Vertex Pharmaceuticals VRTX Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's net debt / EBITDA?
- Vertex Pharmaceuticals (VRTX) reported net debt / EBITDA of -0.7× in Q1 2026.
- What is the long-term trend for Vertex Pharmaceuticals's net debt / EBITDA?
- Over 2 years (2021 to 2023), Vertex Pharmaceuticals's net debt / EBITDA has grown at a 35.1% compound annual growth rate (CAGR), from -2.6× to -4.7×.
- What does net debt / EBITDA mean?
- How many years of operating earnings it would take to pay off the company's net debt.
- How do you interpret net debt / EBITDA?
- Lower is safer; lenders often covenant around 3–4×. A negative value means net cash (more cash than debt), a position of strength. Spikes can reflect a temporary EBITDA dip rather than new borrowing.
- How does net debt / EBITDA compare across companies?
- A standard leverage yardstick across non-financial sectors; covenant thresholds vary by industry cash-flow stability.